Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Receives AUD $11.17 Million Research and Development (R&D) Advance

SYDNEY, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced...
February 29, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Continues Strategic Partnership with Murdoch Children’s Research Institute

SYDNEY, Australia, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced...
February 27, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Expansion of Phase I/II Trial of RECCE® 327 for the Treatment of Diabetic Foot Infections

Independent Safety Committee unanimously agrees that the Phase I/II trial is safe, well tolerated, and fit for expanded accessStudy achieving primary endpoints of safety, tolerability, and efficacy by...
February 07, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Establishes Strategic Partnership in South-East Asia to Accelerate Clinical Program

Memorandum of Understanding (MoU) with leading Indonesian biomedical company PT Etana BiotechnologiesMoU aims to facilitate late-stage clinical trials in Indonesia, supporting the Indonesian...
January 23, 2024 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Reports Positive Phase I/II Trial Results of RECCE® 327 for the Treatment of Diabetic Foot Infections

Phase I/II trial assessing the safety and efficacy of RECCE® 327 (R327), a broad-spectrum anti-infective as a topical treatment, met all primary endpointsR327 was well-tolerated in all patients,...
December 19, 2023 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Awarded AusIndustry Advanced Overseas Finding for Synthetic Anti-Infective Research & Development Program

SYDNEY, Australia, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, today announced it was awarded...
December 18, 2023 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Reports Positive Preclinical Data of RECCE® 327 Against Gonorrhea

Preclinical data continues to demonstrate RECCE® 327’s significant bactericidal activity against Neisseria gonorrhoeae (N. gonorrhoeae), with a 4-log (99.99%) and 3.5-log (>99.9%) reductionN....
November 27, 2023 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the...
November 09, 2023 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Completes Dosing First Subjects at 15-Minute Infusion Rate in a Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Phase I/II study is tracking to meet primary endpointsRECCE® 327 at 3,000mg over 15 minutes marks the fastest infusion rate of a high concentrationCohort fully recruited with remaining subjects to be...
October 25, 2023 08:00 ET | Source: Recce Pharmaceuticals

Recce Pharmaceuticals Announces Safety Committee Approves Faster Infusion Rate in Phase I/II Trial of RECCE® 327 for Urinary Tract Infections and Urosepsis

Independent Safety Committee approves the next cohort dosing of RECCE® 327 (R327) at a faster infusion rate of 15 minutes of 3,000mg via intravenous (IV) administrationR327 was shown to be safe and...